Physician profile
William A Mccormick
NPI 1740411313
$6,246.55
in general payments reported to CMS, 2019-2025
48 companies · $963 in 2025
The $963 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $708 · 2020: $938 · 2021: $1,094 · 2022: $654 · 2023: $1,044 · 2024: $845 · 2025: $963.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,852.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,852.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,039.22 | 2019-2025 | |
| Novo Nordisk INC | $867.24 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $649.61 | 2020-2025 | |
| Glaxosmithkline, LLC. | $643.72 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $290.71 | 2021-2025 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $257.48 | 2019-2023 | Farxiga |
| Lilly USA, LLC | $225.41 | 2020-2024 | Zepbound, Jardiance, Mounjaro |
| Pfizer INC. | $203.91 | 2022-2025 | |
| Amarin Pharma, INC. | $181.93 | 2020-2021 | |
| Horizon Therapeutics Plc | $167.32 | 2020-2022 | |
| Allergan, INC. | $158.06 | 2020 | |
| Corium, LLC | $149.62 | 2023 | Azstarys, Adlarity |
| Sanofi-Aventis U.S. LLC | $117.97 | 2019-2021 | |
| Lundbeck LLC | $108.35 | 2020-2024 | Vyepti |
| Xeris Pharmaceuticals, INC. | $93.10 | 2021-2024 | Gvoke Hypopen |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Mccormick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.